Ones To Watch News
Refine Search
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Pharmaceutical
Shares in Minneapolis-based DiaMedica Therapeutics, a biopharma focused on developing novel treatments for neurological disorders and kidney diseases, were down by a third in pre-market trading on Thursday. 7 July 2022
Biotechnology
Privately-held US biotech Skyhawk Therapeutics has announced an exclusive worldwide collaboration agreement with French pharma major Sanofi to discover and develop novel small molecules that modulate RNA splicing for challenging oncology and immunology targets. 6 July 2022
Pharmaceutical
Urovant Sciences has entered into an exclusive license agreement with French drugmaker Pierre Fabre to register and commercialize vibegron, trade named Gemtesa, for the treatment of overactive bladder (OAB) in certain countries. 5 July 2022
Biotechnology
Gene expression company Syros Pharmaceuticals is to acquire TYME Technologies in a deal that values the oncology-focused biotech at around $60 million. 5 July 2022
Biotechnology
Germany’s CureVa is the latest biopharma company seeking to get a share of the very large profits being made by the most successful COVID-19 vaccines and treatments. 5 July 2022
Pharmaceutical
In line with its commitment to transparency, Spanish plasma-derived medicines company Grifols has disclosed for the seventh consecutive year all payments and other transfers of value related to medicines and medical technology made to healthcare professionals and healthcare organizations in the several European countries listed within the European Federation of Pharmaceutical Industries and Associations’ (EFPIA) scope, including Spain. 5 July 2022
Pharmaceutical
The original news that Japan’s Otsuka had decided to give back rights to vadadustat to Akebia Therapeutics caused the US firm’s shares to slump. However, the disclosure that, as part of the termination, Otsuka has agreed to pay Akebia a settlement fee of $55 million saw its stock leap as much as 40% to $0.50 pre-market on Friday. 2 July 2022
Pharmaceutical
Angion Biomedica saw its shares close down 33% on Thursday and fall a further 6% to $1.07 pre-market today, after the US company announced it will discontinue the Phase II JUNIPER study of ANG-3070 in patients with primary proteinuric kidney diseases. 1 July 2022
Biotechnology
Danish biotech company Genmab has announced its intent to submit a biologics license application (BLA) to the US Food and Drug Administration (FDA) for subcutaneous epcoritamab (DuoBody-CD3xCD20), an investigational bispecific antibody, for the treatment of patients with relapsed/refractory large B-cell lymphoma (LBCL), in the second half of 2022. 1 July 2022
Biotechnology
The US Food and Drug Administration (FDA) yesterday issued a warning that results from a clinical trial show a possible increased risk of death with Copiktra (duvelisib) compared to another medicine to treat a chronic blood cancer called leukemia and a lymphoma, a cancer found in the lymph nodes. 1 July 2022
Biotechnology
NewAmsterdam Pharma, a Dutch clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases, and privately-held Italian Menarini Group have announced an exclusive license agreement for the commercialization of obicetrapib. 29 June 2022
Biotechnology
Switzerland-based Roivant Sciences, which has a long history of creating new companies, has now unveiled Priovant Therapeutics, this time in collaboration with US pharma giant Pfizer, dedicated to developing and commercializing novel therapies for autoimmune diseases with the greatest morbidity and mortality. 28 June 2022
Biotechnology
Shares of Swiss biotech Basilea Pharmaceutica gained more than 3% to 38.45 francs yesterday, after it announced an update on the progress made in the implementation of its strategic focus on anti-infectives. 28 June 2022
Biotechnology
Canadian clinical-stage biotech Zymeworks today announced that it is strengthening its senior leadership team with the appointment of Paul Moore, as chief scientific officer, reporting directly to the chief executive Officer. 27 June 2022
Biotechnology
French drugmaker Ipsen this morning announced it is to acquire US epigenetic therapies firm Epizyme in order to expand its oncology portfolio. 27 June 2022
Biotechnology
Italy’s privately-held Italfarmaco Group has released positive top-line data from its completed Phase III EPIDYS trial with givinostat, the company’s proprietary histone deacetylase (HDAC) inhibitor, in boys with Duchenne muscular dystrophy (DMD). 27 June 2022
Generics
Indian drug major Dr Reddy’s Laboratories, along with its subsidiaries, has acquired a portfolio of branded and generic hospital injectable products from Deer Park, Illinois-based Eton Pharmaceuticals. 27 June 2022
Biotechnology
Shares of Dutch gene therapy company uniQure rose 26% to $19.15 on Thursday as it announced safety and biomarker data from 10 patients enrolled in the low-dose cohort of the ongoing Phase I/II clinical trial of AMT-130 for the treatment of Huntington’s disease (HD). 24 June 2022
Biotechnology
Shares of German biotech BioNTech closed up almost 7% at $132.29 yesterday, after the company – which burst on the scene with its hugely successful COVID-19 vaccine Comirnaty – announced a important development for its wider portfolio. 24 June 2022
Biotechnology
invoX Pharma, a wholly-owned subsidiary of Sino Biopharmaceutical that is focused on research and development (R&D) and business development activities outside of China, today announced that it has entered into a definitive agreement to acquire all of the issued and outstanding shares of F-star Therapeutics’ common stock. 23 June 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze